{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:48:19Z","timestamp":1762876099603,"version":"build-2065373602"},"reference-count":108,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.beem.2019.04.010","type":"journal-article","created":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T12:26:22Z","timestamp":1556281582000},"page":"101276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["New causes of hypophysitis"],"prefix":"10.1016","volume":"33","author":[{"given":"Kevin C.J.","family":"Yuen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Trainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2019.04.010_bib1","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.3174\/ajnr.A1714","article-title":"A\u00a0radiologic score to distinguish autoimmune hypophysitis from nonsecreting pituitary adenoma preoperatively","volume":"30","author":"Gutenberg","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.beem.2019.04.010_bib2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.wneu.2016.07.071","article-title":"Clinical interrogation for unveiling an isolated hypophysitis mimicking pituitary adenoma","volume":"99","author":"Lee","year":"2017","journal-title":"World Neurosurg"},{"key":"10.1016\/j.beem.2019.04.010_bib3","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s002340000311","article-title":"Rathke's cleft cyst associated with hypophysitis: MRI","volume":"42","author":"Daikokuya","year":"2000","journal-title":"Neuroradiology"},{"key":"10.1016\/j.beem.2019.04.010_bib4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11102-017-0852-4","article-title":"A\u00a0case series of atypical features of patients with biopsy-proven isolated IgG4-related hypophysitis and normal serum IgG4 levels","volume":"21","author":"Yuen","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2019.04.010_bib5","first-page":"102","article-title":"Autoimmune hypophysitis may eventually become empty sella","volume":"34","author":"Gao","year":"2013","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.beem.2019.04.010_bib6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jocn.2008.04.031","article-title":"Hypophysitis secondary to ruptured Rathke's cyst mimicking neurosarcoidosis","volume":"16","author":"Janeczko","year":"2009","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.beem.2019.04.010_bib7","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2015-2152","article-title":"Diagnosis of primary hypophsyitis in Germany","volume":"100","author":"Honegger","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.04.010_bib8","series-title":"Oxford textbook of Endocrinology and diabetes","first-page":"259","article-title":"Lymphocytic hypophysitis and other inflammatory conditions of the pituitary","author":"Kravarusic","year":"2011"},{"key":"10.1016\/j.beem.2019.04.010_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.autrev.2008.04.016","article-title":"Pituitary autoimmunity: 30 years later","volume":"7","author":"Caturegli","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2019.04.010_bib10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/er.2004-0011","article-title":"Autoimmune hypophysitis","volume":"26","author":"Caturegli","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2019.04.010_bib11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11102-013-0498-9","article-title":"Hypophysitis due to IgG4-related disease responding to treatment with azathioprine: an alternative to corticosteroid therapy","volume":"17","author":"Caputo","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2019.04.010_bib12","first-page":"e907","article-title":"IgG4-related hypophysitis: case report and literature review","volume":"8","author":"Decker","year":"2016","journal-title":"Cureus"},{"key":"10.1016\/j.beem.2019.04.010_bib13","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1210\/jc.2013-1088","article-title":"A\u00a0case of IgG4-related hypophysitis without pituitary insufficiency","volume":"98","author":"Hattori","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.04.010_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.asjsur.2012.04.013","article-title":"IgG4-related hypophysitis presenting as a pituitary adenoma with systemic disease","volume":"36","author":"Hsing","year":"2013","journal-title":"Asian J Surg"},{"key":"10.1016\/j.beem.2019.04.010_bib15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1507\/endocrj.K08E-034","article-title":"A\u00a0case of IgG4-related multifocal fibrosclerosis complicated by central diabetes insipidus","volume":"55","author":"Isaka","year":"2008","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2019.04.010_bib16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/1756-0500-6-560","article-title":"Autoimmune hypophysitis presenting with intracranial multi-organ involvement: three case reports and review of the literature","volume":"6","author":"Kanoke","year":"2013","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.beem.2019.04.010_bib17","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1210\/jc.2010-2970","article-title":"IgG4-related hypophysitis: a new addition to the hypophysitis spectrum","volume":"96","author":"Leporati","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.04.010_bib18","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2169\/internalmedicine.50.4593","article-title":"IgG4-related systemic disease in a native American man","volume":"50","author":"Patel","year":"2011","journal-title":"Intern Med"},{"key":"10.1016\/j.beem.2019.04.010_bib19","first-page":"140062","article-title":"Histologically confirmed isolated IgG4-related hypophysitis: two case reports in young women","volume":"2014","author":"Sosa","year":"2014","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.beem.2019.04.010_bib20","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2169\/internalmedicine.45.1759","article-title":"IgG4-associated multifocal systemic fibrosis complicating sclerosing sialadenitis, hypophysitis, and retroperitoneal fibrosis, but lacking pancreatic involvement","volume":"45","author":"Tanabe","year":"2006","journal-title":"Intern Med"},{"key":"10.1016\/j.beem.2019.04.010_bib21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2169\/internalmedicine.47.0887","article-title":"Inflammatory pseudotumors in multiple organs associated with elevated serum IgG4 level: recovery by only a small replacement dose of steroid","volume":"47","author":"Tsuboi","year":"2008","journal-title":"Intern Med"},{"key":"10.1016\/j.beem.2019.04.010_bib22","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.humpath.2007.06.011","article-title":"Hypophysitis presented as inflammatory pseudotumor in immunoglobulin G4-related systemic disease","volume":"38","author":"Wong","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.beem.2019.04.010_bib23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/03009740600758110","article-title":"A\u00a0case of Mikulicz's disease (IgG4-related plasmacytic disease) complicated by autoimmune hypophysitis","volume":"35","author":"Yamamoto","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.beem.2019.04.010_bib24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3109\/s10165-006-0518-Y","article-title":"A\u00a0new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease","volume":"16","author":"Yamamoto","year":"2006","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.beem.2019.04.010_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/PAS.0b013e3182027717","article-title":"Subclassification of autoimmune pancreatitis: a histologic classification with clinical significance","volume":"35","author":"Deshpande","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.beem.2019.04.010_bib26","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.beem.2019.04.010_bib27","first-page":"1318","article-title":"Novel strategy to treat a case of recurrent lymphocytic hypophysitis using rituximab","volume":"116","author":"Schreckinger","year":"2012","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.beem.2019.04.010_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1055\/s-0037-1604079","article-title":"Lymphocytic hypophysitis successfully treated with stereotactic radiosurgery: case report and review of the literature","volume":"79","author":"Pekic","year":"2018","journal-title":"J\u00a0Neurol Surg A Cent Eur Neurosurg"},{"key":"10.1016\/j.beem.2019.04.010_bib29","first-page":"118","article-title":"Gamma knife surgery for lymphocytic hypophysitis","volume":"112","author":"Ray","year":"2010","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.beem.2019.04.010_bib30","first-page":"262","article-title":"Primary hypophysitis: a single-center experience in 16 cases","volume":"101","author":"Leung","year":"2004","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.beem.2019.04.010_bib31","first-page":"327","article-title":"Lymphocytic hypophysitis. A review of 145 cases","volume":"150","author":"Beressi","year":"1999","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1016\/j.beem.2019.04.010_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11102-013-0550-9","article-title":"Primary (autoimmune) hypophysitis: a single centre experience","volume":"18","author":"Khare","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2019.04.010_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semcancer.2017.10.001","article-title":"Emerging targets in cancer immunotherapy","volume":"52","author":"Burugu","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.beem.2019.04.010_bib34","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2019.04.010_bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.beem.2019.04.010_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2019.04.010_bib37","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.beem.2019.04.010_bib38","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.04.010_bib39","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beem.2019.04.010_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.04.010_bib41","doi-asserted-by":"crossref","first-page":"230ra245","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.beem.2019.04.010_bib42","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.beem.2019.04.010_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4137\/CMED.S22469","article-title":"Immune checkpoint inhibitor therapy associated hypophysitis","volume":"8","author":"Mahzari","year":"2015","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"10.1016\/j.beem.2019.04.010_bib44","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.beem.2019.04.010_bib45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.beem.2019.04.010_bib46","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2019.04.010_bib47","doi-asserted-by":"crossref","first-page":"pky021","DOI":"10.1093\/jncics\/pky021","article-title":"The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management","volume":"2","author":"Girotra","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.beem.2019.04.010_bib48","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-16-0054","article-title":"SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: emergency management of acute adrenal insufficiency (adrenal crisis) in adult patients","volume":"5","author":"Arlt","year":"2016","journal-title":"Endocr Connect"},{"key":"10.1016\/j.beem.2019.04.010_bib49","article-title":"French Endocrine Society Guidance on endocrine side-effects of immunotherapy","author":"Castinetti","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2019.04.010_bib50","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beem.2019.04.010_bib51","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-18-0068","article-title":"SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1016\/j.beem.2019.04.010_bib52","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/art.39132","article-title":"International consensus guidance statement on the management and treatment of IgG4-related disease","volume":"67","author":"Khosroshahi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.beem.2019.04.010_bib53","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1093\/rheumatology\/kev203","article-title":"Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients","volume":"54","author":"Lin","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.beem.2019.04.010_bib54","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1507\/endocrj.K09E-277","article-title":"Pituitary and stalk lesions (infundibulo-hypophysitis) associated with immunoglobulin G4-related systemic disease: an emerging clinical entity","volume":"56","author":"Shimatsu","year":"2009","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2019.04.010_bib55","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/BOR.0b013e3283412f4a","article-title":"Pathogenesis of IgG4-related disease","volume":"23","author":"Zen","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.beem.2019.04.010_bib56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MD.0b013e3182433d77","article-title":"IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry","volume":"91","author":"Ebbo","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.beem.2019.04.010_bib57","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s11102-016-0773-7","article-title":"Critical review of IgG4-related hypophysitis","volume":"20","author":"Shikuma","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2019.04.010_bib58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1530\/EJE-13-0642","article-title":"The prevalence of IgG4-related hypophysitis in 170 consecutive patients with hypopituitarism and\/or central diabetes insipidus and review of the literature","volume":"170","author":"Bando","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2019.04.010_bib59","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bpa.12459","article-title":"IgG4-related hypophysitis is highly prevalent among cases of histologically confirmed hypophysitis","volume":"27","author":"Bernreuther","year":"2017","journal-title":"Brain Pathol"},{"key":"10.1016\/j.beem.2019.04.010_bib60","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1002\/art.34593","article-title":"Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations","volume":"64","author":"Stone","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beem.2019.04.010_bib61","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/BOR.0b013e3283413469","article-title":"Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis","volume":"23","author":"Sah","year":"2011","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.beem.2019.04.010_bib62","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2169\/internalmedicine.8446-16","article-title":"Prednisolone-responsive postpartum IgG4-related hypophysitis","volume":"57","author":"Koide","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.beem.2019.04.010_bib63","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus statement on the pathology of IgG4-related disease","volume":"25","author":"Deshpande","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.beem.2019.04.010_bib64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.anl.2016.10.011","article-title":"Recent advances in knowledge regarding the head and neck manifestations of IgG4-related disease","volume":"44","author":"Takano","year":"2017","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.beem.2019.04.010_bib65","article-title":"Clinical course of pituitary function and image in IgG4-related hypophysitis","volume":"2017","author":"Anno","year":"2017","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.beem.2019.04.010_bib66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4137\/CCRep.S15352","article-title":"A\u00a0case of IgG4-related hypophysitis presented with hypopituitarism and diabetes insipidus","volume":"8","author":"Harano","year":"2015","journal-title":"Clin Med Insights Case Rep"},{"key":"10.1016\/j.beem.2019.04.010_bib67","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1507\/endocrj.K09E-356","article-title":"Long-term clinical course of IgG4-related systemic disease accompanied by hypophysitis","volume":"57","author":"Hori","year":"2010","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2019.04.010_bib68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1507\/endocrj.EJ13-0407","article-title":"Prednisolone markedly reduced serum IgG4 levels along with the improvement of pituitary mass and anterior pituitary function in a patient with IgG4-related infundibulo-hypophysitis","volume":"61","author":"Iseda","year":"2014","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2019.04.010_bib69","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2169\/internalmedicine.8446-16","article-title":"Prednisolone-responsive postpartum IgG4-related hypophysitis","volume":"57","author":"Koide","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.beem.2019.04.010_bib70","first-page":"1","article-title":"Current concepts in the treatment of autoimmune pancreatitis","volume":"8","author":"Chari","year":"2007","journal-title":"JOP"},{"key":"10.1016\/j.beem.2019.04.010_bib71","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1136\/gut.2008.172908","article-title":"Standard steroid treatment for autoimmune pancreatitis","volume":"58","author":"Kamisawa","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.beem.2019.04.010_bib72","doi-asserted-by":"crossref","first-page":"e6934","DOI":"10.1097\/MD.0000000000006934","article-title":"Rituximab was used to treat recurrent IgG4-related hypophysitis with ophthalmopathy as the initial presentation: a case report and literature review","volume":"96","author":"Gu","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.beem.2019.04.010_bib73","doi-asserted-by":"crossref","first-page":"622","DOI":"10.2176\/nmc.49.622","article-title":"Hypophysitis presenting with atypical rapid deterioration: with special reference to immunoglobulin G4-related disease-case report","volume":"49","author":"Osawa","year":"2009","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"10.1016\/j.beem.2019.04.010_bib74","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2016-12-757823","article-title":"Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults","volume":"130","author":"Milne","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beem.2019.04.010_bib75","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1210\/jc.2015-3357","article-title":"Endocrine manifestations in a monocentric cohort of 64 patients with Erdheim-Chester Disease","volume":"101","author":"Courtillot","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.04.010_bib76","doi-asserted-by":"crossref","first-page":"774","DOI":"10.2967\/jnumed.117.200741","article-title":"(18)F-FDG PET\/CT in Erdheim-Chester disease: imaging findings and potential BRAF mutation biomarker","volume":"59","author":"Young","year":"2018","journal-title":"J\u00a0Nucl Med"},{"issue":"12","key":"10.1016\/j.beem.2019.04.010_bib77","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1634\/theoncologist.2018-0295","article-title":"FDA approval summary: vemurafenib for the treatment of patients with Erdheim-Chester disease with the BRAFV600 mutation","volume":"23","author":"O'Neal","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.beem.2019.04.010_bib78","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4132\/jptm.2017.10.16","article-title":"Erdheim-Chester disease involving lymph nodes and liver clinically mimicking lymphoma: a case report","volume":"52","author":"Sung","year":"2018","journal-title":"J\u00a0Pathol Transl Med"},{"key":"10.1016\/j.beem.2019.04.010_bib79","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.mayocpiqo.2018.05.001","article-title":"Dabrafenib and trametinib treatment for Erdheim-Chester disease with brain stem involvement","volume":"2","author":"Al Bayati","year":"2018","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10.1016\/j.beem.2019.04.010_bib80","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/bjh.14284","article-title":"Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease","volume":"180","author":"Cohen Aubart","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beem.2019.04.010_bib81","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3960\/jslrt.18015","article-title":"Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: a case report","volume":"58","author":"Tamura","year":"2018","journal-title":"J\u00a0Clin Exp Hematop"},{"key":"10.1016\/j.beem.2019.04.010_bib82","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood-2015-01-620377","article-title":"Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial","volume":"126","author":"Gianfreda","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beem.2019.04.010_bib83","first-page":"290","article-title":"Anti-PIT-1 antibody syndrome; a novel clinical entity leading to hypopituitarism","volume":"12","author":"Bando","year":"2015","journal-title":"Pediatr Endocrinol Rev"},{"key":"10.1016\/j.beem.2019.04.010_bib84","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1089\/thy.2014.0028","article-title":"Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement","volume":"24","author":"Jonklaas","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2019.04.010_bib85","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ecl.2007.04.007","article-title":"The nonthyroidal illness syndrome","volume":"36","author":"Adler","year":"2007","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.beem.2019.04.010_bib86","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1507\/endocrj.50.697","article-title":"Anti-alpha-enolase antibodies in pituitary disease","volume":"50","author":"Tanaka","year":"2003","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2019.04.010_bib87","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF03347415","article-title":"Lymphocytic hypophysitis: report of two biopsy-proven cases and one suspected case with pituitary autoantibodies","volume":"30","author":"Bensing","year":"2007","journal-title":"J\u00a0Endocrinol Investig"},{"key":"10.1016\/j.beem.2019.04.010_bib88","first-page":"288","article-title":"Antipituitary antibodies in patients with lymphocytic hypophysitis","volume":"55","author":"Takao","year":"2001","journal-title":"Horm Res"},{"key":"10.1016\/j.beem.2019.04.010_bib89","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1530\/eje.0.1470767","article-title":"Detection of autoantibodies against the pituitary-specific proteins in patients with lymphocytic hypophysitis","volume":"147","author":"Tanaka","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2019.04.010_bib90","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1530\/EJE-11-1015","article-title":"Identification of TPIT and other novel autoantigens in lymphocytic hypophysitis: immunoscreening of a pituitary cDNA library and development of immunoprecipitation assays","volume":"166","author":"Smith","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2019.04.010_bib91","doi-asserted-by":"crossref","first-page":"E946","DOI":"10.1210\/jc.2014-4209","article-title":"Rabphilin-3A as a targeted autoantigen in lymphocytic infundibulo-neurohypophysitis","volume":"100","author":"Iwama","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.04.010_bib92","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s13139-017-0494-5","article-title":"The utility of FDG PET\/CT in IgG4-related disease with a focus on coronary artery involvement","volume":"52","author":"Huang","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.beem.2019.04.010_bib93","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/RLU.0000000000002253","article-title":"Hepatic involvement of IgG4-related disease presenting as multiple hypermetabolic masses on FDG PET\/CT","volume":"43","author":"Pan","year":"2018","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.beem.2019.04.010_bib94","series-title":"Endotext","article-title":"Hypophysitis","author":"Prete","year":"2000"},{"key":"10.1016\/j.beem.2019.04.010_bib95","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.04.010_bib96","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.beem.2019.04.010_bib97","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2019.04.010_bib98","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2019.04.010_bib99","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3892\/ol.2015.4069","article-title":"Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma","volume":"11","author":"Khoja","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.beem.2019.04.010_bib100","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2019.04.010_bib101","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12020-017-1289-2","article-title":"Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab","volume":"58","author":"Brilli","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2019.04.010_bib102","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.beem.2019.04.010_bib103","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.annemergmed.2018.04.019","article-title":"Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center","volume":"73","author":"El Majzoub","year":"2019","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.beem.2019.04.010_bib104","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2019.04.010_bib105","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.04.010_bib106","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.04.010_bib107","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.04.010_bib108","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X19300193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X19300193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:54:39Z","timestamp":1761497679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X19300193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":108,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1521690X19300193"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2019.04.010","relation":{},"ISSN":["1521-690X"],"issn-type":[{"type":"print","value":"1521-690X"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New causes of hypophysitis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2019.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101276"}}